ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genetic and genomic testing, today announced enhancements to their portfolio of tests for the detection of genetic mutations ...

Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups highlighting the importance of proactive reanalysis offerings like Ambry ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

Ambry Genetics first implemented RNA testing in 2016 as part of a research and validation pilot and subsequently launched it commercially in 2019 as +RNAinsight®. This advancement transformed ...

Evanston, Ill.-based NorthShore University HealthSystem’s center for personalized medicine will partner with Aliso Viejo, Calif.-based Ambry Genetics to offer 10,000 patients genetic testing. Ambry ...

Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare by ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Tempus AI announced today it is acquiring genetic testing ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its ...

In hopes of gifting researchers a tool they can use to identify links between genes and disease, Viejo, Calif.-based DNA testing firm Ambry Genetics made public a database containing the information ...

Ambry Genetics, a subsidiary of Tempus AI, announced completion of 1 million DNA/RNA tests for hereditary cancer and rare ...

Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data ...